Cargando…
New Ruthenium-Cyclopentadienyl Complexes Affect Colorectal Cancer Hallmarks Showing High Therapeutic Potential
Colorectal cancer (CRC) is among the most deadly cancers worldwide. Current therapeutic strategies have low success rates and several side effects. This relevant clinical problem requires the discovery of new and more effective therapeutic alternatives. Ruthenium drugs have arisen as one of the most...
Autores principales: | Brás, Ana Rita, Fernandes, Pedro, Moreira, Tiago, Morales-Sanfrutos, Julia, Sabidó, Eduard, Antunes, Alexandra M. M., Valente, Andreia, Preto, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302444/ https://www.ncbi.nlm.nih.gov/pubmed/37376178 http://dx.doi.org/10.3390/pharmaceutics15061731 |
Ejemplares similares
-
Ruthenium(II)–Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs
por: Teixeira-Guedes, Catarina, et al.
Publicado: (2022) -
A New Family of Iron(II)-Cyclopentadienyl Compounds Shows Strong Activity against Colorectal and Triple Negative Breast Cancer Cells
por: Pilon, Adhan, et al.
Publicado: (2020) -
Fighting Multidrug
Resistance with Ruthenium–Cyclopentadienyl
Compounds: Unveiling the Mechanism of P-gp Inhibition
por: Teixeira, Ricardo G., et al.
Publicado: (2023) -
Biotinylated Polymer-Ruthenium Conjugates: In Vitro and In Vivo Studies in a Triple-Negative Breast Cancer Model
por: Côrte-Real, Leonor, et al.
Publicado: (2022) -
Antioxidant Activity of Ruthenium Cyclopentadienyl Complexes Bearing Succinimidato and Phthalimidato Ligands
por: Juszczak, Michał, et al.
Publicado: (2022)